Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth
BioSpace
Eli Lilly's $19.8 billion revenue for the first quarter could have been higher if not for declining prices for key medicines like Zepbound, Mounjaro and Taltz.
pharminent
April 30, 2026 (Last updated: April 30, 2026)
BioSpace
Eli Lilly’s $19.8 billion revenue for the first quarter could have been higher if not for declining prices for key medicines like Zepbound, Mounjaro and Taltz.
